MNG565
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- CHOLESTEROL_HOMEOSTASIS+0.456
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.445
- INTERFERON_ALPHA_RESPONSE+0.407
- E2F_TARGETS+0.364
- OXIDATIVE_PHOSPHORYLATION+0.288
- DNA_REPAIR+0.287
- INTERFERON_GAMMA_RESPONSE+0.269
- G2M_CHECKPOINT+0.266
- BILE_ACID_METABOLISM+0.256
- APOPTOSIS+0.252
Top 10 suppressed
- HEDGEHOG_SIGNALING-0.335
- TGF_BETA_SIGNALING-0.271
- WNT_BETA_CATENIN_SIGNALING-0.266
- ANDROGEN_RESPONSE-0.204
- KRAS_SIGNALING_UP-0.172
- UV_RESPONSE_DN-0.168
- PROTEIN_SECRETION-0.148
- PANCREAS_BETA_CELLS-0.136
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.084
- HEME_METABOLISM-0.034
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-BA-A6DD-01A-12R-A31N-07 | — | — | 0.805 |
| 2 | MNG1266 | — | — | 0.802 |
| 3 | SRR25617850 | — | C | 0.802 |
| 4 | 1a68a242-045b-4566-afd7-192df87b02d3 | — | — | 0.784 |
| 5 | 77907EB2-E529-4633-A580-C6DD7993A704 | — | — | 0.779 |
| 6 | MNG477 | — | — | 0.772 |
| 7 | TCGA-39-5011-01A-01R-1443-07 | — | cohortA1 | 0.770 |
| 8 | TCGA-AO-A0J2-01A-11R-A034-07 | — | C | 0.759 |
| 9 | MBCProject_2741_T1_RNA | — | B | 0.758 |
| 10 | TCGA-A8-A07Z-01A-11R-A00Z-07 | — | B | 0.757 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 39 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| CHOLESTEROL_HOMEOSTASIS | 0.456 | Remibrutinib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.445 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.407 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.364 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.288 | Remibrutinib | — uncovered |
| DNA_REPAIR | 0.287 | Idelalisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.269 | Idelalisib | — uncovered |
| G2M_CHECKPOINT | 0.266 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.256 | Inavolisib | — uncovered |
| APOPTOSIS | 0.252 | Idelalisib | — uncovered |
| GLYCOLYSIS | 0.230 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.224 | Idelalisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.220 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.203 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.203 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.202 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.192 | Idelalisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.173 | Idelalisib | — uncovered |
| COAGULATION | 0.164 | Binimetinib | — uncovered |
| COMPLEMENT | 0.160 | Inavolisib | — uncovered |